These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 27615536)

  • 21. The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Besse B; Brahmer JR; Crinò L; Felip E; de Marinis F
    Clin Lung Cancer; 2016 May; 17(3):161-8. PubMed ID: 26908078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Dempke WC; Sellmann L; Fenchel K; Edvardsen K
    Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
    Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immune checkpoint inhibitors in lung cancer].
    Koleczko S; Wolf J
    Internist (Berl); 2020 Jul; 61(7):676-681. PubMed ID: 32462250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of Advanced or Postoperative Recurrent Non-small Lung Cancer Cases Treated with Nivolumab].
    Ichiki Y; Iwanami T; Kakizoe K; Hamatsu T; Suehiro T; Yoneda K; Tanaka F; Sugimachi K
    J UOEH; 2017; 39(4):291-297. PubMed ID: 29249742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
    Leventakos K; Mansfield AS
    BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
    Garassino MC; Crinò L; Catino A; Ardizzoni A; Cortesi E; Cappuzzo F; Bordi P; Calabrò L; Barbieri F; Santo A; Altavilla G; Ambrosio F; Mini E; Vasile E; Morgillo F; Scoppola A; Bengala C; Follador A; Tedde N; Giannarelli D; Lo Russo G; Vitiello F
    Tumour Biol; 2018 Nov; 40(11):1010428318815047. PubMed ID: 30486741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
    Reck M; Mellemgaard A; von Pawel J; Gottfried M; Bondarenko I; Cheng Y; Zarogoulidis K; Luft A; Bennouna J; Barrueco J; Aboshady H; Hocke J; Kaiser R; Douillard JY;
    Lung Cancer; 2015 Nov; 90(2):267-73. PubMed ID: 26415992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nivolumab, a new hope in non-small cell lung cancer].
    Flippot R; Fallet V; Besse B; Massard C; Wislez M; Vignot S
    Bull Cancer; 2015 Dec; 102(12):1046-52. PubMed ID: 26585939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.
    Kashima J; Okuma Y; Shimizuguchi R; Chiba K
    Cancer Immunol Immunother; 2018 Jan; 67(1):61-65. PubMed ID: 28913619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial.
    Salvati F; Rasi G; Portalone L; Antilli A; Garaci E
    Anticancer Res; 1996; 16(2):1001-4. PubMed ID: 8687090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
    Remon J; Besse B; Soria JC
    BMC Med; 2017 Mar; 15(1):55. PubMed ID: 28285592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
    Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
    J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
    Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
    Waqar SN; Morgensztern D
    Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.